

FORM 11

NOTICE OF PROPOSED STOCK OPTION GRANT OR AMENDMENT

Name of Listed Issuer: Pharmadrug Inc. (the "Issuer").

Trading Symbol: PHRX

Date: August 30, 2021

1. New Options Granted:

Date of Grant: August 30, 2021

Name of Optionee	Position (Director/ Officer/ Employee/ Consultant/ Management Company)	Insider Yes or No?	No. of Optioned Shares	Exercise Price	Expiry Date	No. of Options Granted in Past 12 Months
David Kideckel	Officer	Yes	750,000	\$0.06	August 30, 2026	N/A

Total Number of optioned shares proposed for acceptance: 750,000.

2. Other Presently Outstanding Options:

Name of Optionee	No. of Optioned Shares ⁽¹⁾	Exercise Price	Original Date of Grant	Expiry Date
Daniel Cohen	250,000	\$0.31	24-Sep-18	24-Sep-21
Tim Wilkinson	50,000	\$0.31	24-Sep-18	24-Sep-21
Terrence Booth	5,000,000	\$0.11	31-May-20	31-May-25
Jeffrey Stevens	500,000	\$0.11	31-May-20	31-May-25
Daniel Cohen	3,000,000	\$0.05	Aug 31, 2020	Aug 31, 2025
Jeremy Friederer aka Harry Resin	2,000,000	\$0.05	Aug 31, 2020	Aug 31, 2025
Michael Forbes	1,000,000	\$0.05	Aug 31, 2020	Aug 31, 2025
Al Quong	750,000	\$0.05	Aug 31, 2020	Aug 31, 2025
Paul McClory	500,000	\$0.05	Aug 31, 2020	Aug 31, 2025
Robert Schwartz	500,000	\$0.05	Aug 31, 2020	Aug 31, 2025
Nikolai Vassev	500,000	\$0.05	Aug 31, 2020	Aug 31, 2025
Keith Li	250,000	\$0.05	Aug 31, 2020	Aug 31, 2025
2653438 Ontario Inc.	1,000,000	\$0.06	Dec 8, 2020	Dec 8, 2025
Jeremy Friederer	750,000	\$0.085	Feb 4, 2021	Feb 4, 2026
Michael Forbes	500,000	\$0.085	Feb 4, 2021	Feb 4, 2026
Al Quong	500,000	\$0.085	Feb 4, 2021	Feb 4, 2026
Paul McClory	500,000	\$0.085	Feb 4, 2021	Feb 4, 2026
Robert Schwartz	500,000	\$0.085	Feb 4, 2021	Feb 4, 2026
Nikolai Vassez	500,000	\$0.085	Feb 4, 2021	Feb 4, 2026
Keith Li	250,000	\$0.085	Feb 4, 2021	Feb 4, 2026
Daniel Cohen	750,000	\$0.085	Feb 4, 2021	Feb 4, 2026
Rody Lazar	100,000	\$0.085	Feb 4, 2021	Feb 4, 2026
Paul Van Slyke	2,000,000	\$0.09	May 12, 2021	May 12, 2026

(1) Set out number of optioned shares for each grant with different terms.

3. Additional Information

- (a) If shareholder approval was required for the grant of options (including prior approval of a stock option plan), state the date that the shareholder meeting approving the grant was or will be held. N/A; shareholder approval not required.
- (b) State the date of the news release announcing the grant of options.
August 30, 2021
- (c) State the total issued and outstanding share capital at the date of grant or amendment. 340,816,383
- (d) State, as a percentage of the issued and outstanding shares of the Issuer indicated in (c) above, the aggregate number of shares that are subject to incentive stock options, including new options, amended options and other presently outstanding options. 6.57%
- (e) If the new options are being granted pursuant to a stock option plan, state the number of remaining shares reserved for issuance under the plan.
11,681,638
- (f) If the Issuer has completed a public distribution of its securities within 90 days of the date of grant, state the per share price paid by the public investors.
N/A
- (g) Describe the particulars of any proposed material changes in the affairs of the Issuer. N/A

4. Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such

term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).

4. All of the information in this Form 11 Notice of Proposed Stock Option Grant or Amendment is true.

Dated September 3, 2021 .

Daniel Cohen
Name of Director or Senior
Officer

"Daniel Cohen"
Signature

Director & Chief Executive Officer
Official Capacity